Eris Lifesciences Ltd
Ticker: ERIS
Decent
48/100
☆ Add to Watchlist
Investing Reference
Price
1584.10
Market Cap
21577.59
Debt/Equity
0.7574
ROE %
10.836
PB
6.5951
Promoter %
54.835
Pledge %
9.282
1Y Rev Growth %
40.713
5Y Rev Growth %
21.855
NP Margin %
12.021
NP Margin 5Y Avg %
22.291
Trading Reference
1M Return %
-4.826
6M Return %
14.640
1Y Return %
15.674
% Away 52W High
20.573
% Away 52W Low
44.377
Daily Volume
45605
Investment Verdict
Risky
Score 49/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 28/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Eris Lifesciences Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. If the stock breaks above the resistance level, there is a strong potential for upward movement. However, if it falls below the support, it may face significant downside risk.
Upside Probability: 20% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
T
Timken India Ltd
Timken India Ltd shows a decent investment opportunity with consistent growth and profitability metrics, though some risks remain in execution and governance.
View details
A
Astrazeneca Pharma India Ltd
Astrazeneca Pharma India Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
View details
C
Chalet Hotels Ltd
Chalet Hotels Ltd shows potential for growth in a recovering sector, but faces challenges in profitability and valuation metrics.
View details
M
Mangalore Refinery and Petrochemicals Ltd
Mangalore Refinery and Petrochemicals Ltd shows potential but faces several challenges that could impact future performance.
View details
K
Kalpataru Projects International Ltd
Kalpataru Projects International Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and execution risks.
View details
A
Aadhar Housing Finance Ltd
Aadhar Housing Finance Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
View details
S
Sun Tv Network Ltd
Sun TV Network Ltd shows potential but faces significant challenges in growth and market adaptation.
View details
P
PNB Housing Finance Ltd
PNB Housing Finance Ltd shows potential in a growing sector but faces significant challenges in profitability and valuation metrics.
View details
C
Chambal Fertilisers and Chemicals Ltd
Chambal Fertilisers shows potential for growth but faces challenges in profitability and execution risks.
View details
S
Sundram Fasteners Ltd
Sundram Fasteners Ltd shows decent potential with moderate risks, but investors should be cautious about valuation and execution challenges.
View details
O
Onesource Specialty Pharma Ltd
Onesource Specialty Pharma Ltd shows potential in a growing sector, but faces challenges in execution and profitability. Caution is advised due to valuation concerns and market risks.
View details
C
CESC Ltd
CESC Ltd shows potential risks in growth and profitability, making it a risky investment at this time.
View details
P
PTC Industries Ltd
PTC Industries Ltd shows potential in a growing sector, but inconsistent financial performance and governance concerns pose significant risks.
View details
J
JSW Holdings Ltd
JSW Holdings Ltd shows potential for growth with a decent balance sheet and profitability metrics, but caution is advised due to some governance concerns and execution risks.
View details
S
Schneider Electric Infrastructure Ltd
Schneider Electric Infrastructure Ltd shows potential in a future-ready sector with decent growth prospects, but faces challenges in profitability and execution risks.
View details
E
eClerx Services Limited
eClerx Services Limited shows decent potential with consistent growth and a solid business model, but caution is advised due to some cash flow and governance concerns.
View details
Business Overview
Eris Lifesciences Ltd is a prominent Indian pharmaceutical company focused on developing and marketing high-quality generic and specialty medications. Catering primarily to healthcare providers and patients, Eris plays a crucial role in enhancing the accessibility of essential medicines in India. With a commitment to innovation and quality, the company is well-positioned to address the growing healthcare needs of the population.
- Leading player in the Indian pharmaceutical sector
- Specializes in generic and specialty medications
- Focus on quality and innovation
- Strong commitment to patient accessibility
- Robust growth potential in a growing market
Investment Thesis
Eris Lifesciences Ltd stands out due to its credible promoter group, robust growth in digital services, and attractive valuation compared to peers. This combination positions the company for sustained growth and investor confidence.
- Strong credibility of the promoter group enhances trust and governance.
- Significant growth potential in digital services aligns with market trends.
- Valuation metrics indicate Eris is attractively priced against industry peers.
- Diversified product portfolio supports revenue stability and growth.
- Focus on innovation ensures competitive advantage in the pharma sector.
Opportunity vs Risk
Opportunities
- Strong growth in chronic therapies
- Expanding product portfolio
- Rising demand for affordable medicines
- Strategic partnerships with healthcare providers
Risks ⚠️
- Regulatory challenges in pharmaceuticals
- Intense competition in generics
- Dependency on key product sales
- Market volatility affecting stock price
Peer Perspective
Eris Lifesciences Ltd trades at a premium to peers like Sun Pharmaceutical and Cipla, reflecting its strong growth potential. A sustained improvement in margins could trigger a favorable rerating in the competitive pharma landscape.
Future Outlook
Eris Lifesciences Ltd is well-positioned for growth, driven by its expanding product portfolio and market presence; however, successful execution and cost control will be crucial to fully realize its potential in the competitive landscape.
AI FAQs for Retail Users
- Q: What does Eris Lifesciences Ltd do?A: Eris Lifesciences Ltd is a pharmaceutical company focused on developing and marketing branded prescription drugs.
- Q: Is Eris Lifesciences Ltd a profitable company?A: Eris Lifesciences has reported profits in recent years, but profitability can vary based on market conditions.
- Q: What are the key products of Eris Lifesciences?A: The company offers a range of products in chronic therapy areas, including diabetes and cardiovascular health.
- Q: How can I invest in Eris Lifesciences Ltd?A: You can invest by purchasing shares through a registered stockbroker or online trading platform.
- Q: What factors affect Eris Lifesciences Ltd's stock price?A: Stock price can be influenced by company performance, market trends, regulatory changes, and overall economic conditions.
📊 Stock Investment Checklist (100 Points)
Eris Lifesciences Ltd • Updated: 2025-09-16 20:43:52
-
10BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighConsistent revenue growth over the past few years.
-
10ProfitabilityHighROE and ROCE are healthy, but OCF is fluctuating.
-
8ValuationHighP/E and P/B ratios are slightly above industry average.
-
7BalanceHighDebt levels are manageable, but liquidity could improve.
-
9GovernanceHighPromoter holding is strong, minimal pledging.
-
6DriversGoodGrowth drivers exist, but execution risks are present.
-
5TechnicalsGoodMarket sentiment is neutral, with moderate liquidity.
Final Score & Verdict
Score 48 / 100
• Decent
Eris Lifesciences Ltd shows decent potential with consistent growth and profitability metrics, but faces challenges in valuation and execution risks.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100